Stock AnalizJazz Pharmaceuticals plc JAZZ
Biotechnology: Pharmaceutical Preparations · IPO 2007 · data as of November 13, 2026
Jazz Pharmaceuticals plc (JAZZ) is a healthcare company listed in the US with a market value of about $15.5B. In the twelve months to September 30, 2026 it had revenue of $4.7B and net income of $206M, a net margin of 4.4%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (1/5); the weakest is value (1/5).
Key numbers: a P/E of 78.7, a price to free cash flow of 9.6, 5-year revenue growth of 13% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 44% below the current price.
Score: 1.0 / 5
Checks passed
- P/FCF below 20
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7B | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B | $2.4B | $2.2B | $1.9B | $1.6B | $1.5B |
| Net income | $206M | -$356M | $560M | $415M | -$224M | -$330M | $239M | $523M | $447M | $488M | $397M |
| Free cash flow | $1.6B | $1.3B | $1.4B | $1.1B | $1.2B | $751M | $885M | $736M | $779M | $664M | $583M |
| EPS (diluted) | $3.07 | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 |
| Net margin | 4.4% | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% |
| ROIC | — | -2.5% | 5.5% | 4.8% | -0.4% | 1.3% | 5.6% | 8.6% | 11.6% | 9.7% | 11.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 22 analysts is $296.77, 23% above the current price; targets range from $220.00 to $330.00; the consensus rating is “Strong buy”; expected EPS is $14.94 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Jazz Pharmaceuticals’s P/E ratio?
About 78.7, based on the last twelve months of diluted earnings per share (forward P/E about 9.5).
Is Jazz Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 44% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Jazz Pharmaceuticals pay a dividend?
Not currently.
Is Jazz Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Jazz Pharmaceuticals scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.